在患有肺癌的患者中,对类固醇耐药性免疫相关不良事件进行二线免疫抑制剂的使用
Shinsuke Ogusu1, Yuhei Harutani2, Takehiro Tozuka3
1Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Cancer immunology, immunotherapy : CII
|August 28, 2023
概括
二线免疫抑制剂在肺癌患者中有效治疗严重的免疫相关不良事件 (irAEs),尽管肺炎的反应率较低. 谨慎的治疗时间与IRAE解决相关.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于二线免疫抑制剂在管理免疫相关不良事件 (irAEs) 方面的证据有限.
- 严重的irrAEs需要进一步研究各种癌症的有效治疗策略.
研究的目的:
- 评估二线免疫抑制剂对肺癌患者的皮质类固醇耐药性IRE的疗效.
- 分析这些治疗对肺癌进展和患者结局的影响.
主要方法:
- 对4589名接受免疫检查点抑制剂治疗的患者进行了描述性分析.
- 专注于73名患有需要二线免疫抑制剂的irrAEs的患者.
主要成果:
- 在肺癌患者中,二线免疫抑制剂的总体应答率为72.2%.
- 与肝胆道疾病 (86.7%) 和肠炎 (92.9%) 相比,肺炎的应答率较低 (42.3%).
- 开始二线免疫抑制剂的时间与irAE解决相关;中位数无进展生存时间为2.1个月.
结论:
- 二线免疫抑制剂对肺癌irrAEs有效,但特定的irrAEs如肺炎需要量身定制的方法.
- 感染是一个显著的风险 (27.4%),有潜在的死亡率 (5.5%).
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
487
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
487
COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
298
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
298
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Antiasthma Drugs: Leukotriene Modifiers
353
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
353


